Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

Literature DB >> 15173102

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

Gary J Kelloff¹, Donald S Coffey, Bruce A Chabner, Adam P Dicker, Kathryn Z Guyton, Perry D Nisen, Howard R Soule, Anthony V D'Amico.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15173102 DOI： 10.1158/1078-0432.CCR-03-0788

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Authors: Elba C Etchebehere; Denái R Milton; John C Araujo; Nancy M Swanston; Homer A Macapinlac; Eric M Rohren
Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-29 Impact factor: 9.236

2. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

Authors: Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Donald Berry; Noel Clarke; Laurence Collette; Anthony D'Amico; Richard De Abreu Lourenco; James Dignam; Mario Eisenberger; Nicholas James; Karim Fizazi; Silke Gillessen; Yohann Loriot; Nicolas Mottet; Wendy Parulekar; Howard Sandler; Daniel E Spratt; Matthew R Sydes; Bertrand Tombal; Scott Williams; Christopher J Sweeney
Journal: J Clin Oncol Date: 2020-06-18 Impact factor: 44.544

Review 3. Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors: Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal: Mol Diagn Ther Date: 2006 Impact factor: 4.074

Review 4. A review on nanomaterial-based field effect transistor technology for biomarker detection.

Authors: Leila Syedmoradi; Anita Ahmadi; Michael L Norton; Kobra Omidfar
Journal: Mikrochim Acta Date: 2019-11-01 Impact factor: 5.833

5. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

Authors: Michael J Morris; Timothy Akhurst; Steven M Larson; Marisa Ditullio; Elaina Chu; Karen Siedlecki; David Verbel; Glenn Heller; W Kevin Kelly; Susan Slovin; Lawrence Schwartz; Howard I Scher
Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531

10. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.

Authors: Xing Hua; Lina Yu; Wenhai Pan; Xiaoxiao Huang; Zexiao Liao; Qi Xian; Li Fang; Hong Shen
Journal: Diagn Pathol Date: 2012-09-24 Impact factor: 2.644

Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer.

1. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

2. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

Review 3. Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Review 4. A review on nanomaterial-based field effect transistor technology for biomarker detection.

5. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

6. Clinical aspects of mCRPC management in patients treated with radium-223.

7. Ligand-receptor interactions between surfaces: the role of binary polymer spacers.

8. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.

9. Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice.

10. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.